Define the isomer, individual amounts and serving load before calling a gummy “inositol.”
Sucotond USA coordinates non-confidential feasibility review for U.S. brands planning custom inositol gummies. The review connects the named myo-inositol and D-chiro-inositol components, individual amounts and any requested ratio, supplier materials, serving and piece count, gummy matrix, analytical method, label, package and evidence before a commercial commitment.
This is a custom-project service page, not a claim that one stocked isomer, ratio, amount, method, formula or shelf life fits every project.
Project Starting Point“Inositol” alone is not a complete product specification
In a reviewable brief, myo-inositol and D-chiro-inositol are separate specification fields. The project also distinguishes individual amounts from a calculated ratio, and the ingredient specification from the finished gummy and its measurement system.
Myo-inositol
Name the exact ingredient, supplier material, lot and composition basis. Do not rely on the shorter word “inositol” when another isomer is also part of the concept.
D-chiro-inositol
Treat this as its own formula and evidence field. Its identity, amount, supplier documentation and regulatory review cannot be inferred from a myo-inositol reference.
Individual amounts and ratio
A ratio is calculated from two defined amounts on a stated basis. The file must preserve each amount, serving, units and tolerances instead of recording only one ratio.
Gummy matrix and method
Sugars, acids, water, flavors and other carbohydrates can affect sample preparation or separation. Method suitability belongs to the actual analytes and finished matrix.
Eight decisions make the request reviewable
1. Name each intended ingredient
- Myo-inositol, D-chiro-inositol or another specifically reviewed component
- Supplier, grade, physical form and lot-document expectations
- Identity and composition evidence available for review
2. State individual amounts first
- Amount of each component per serving
- Any requested ratio and its calculation basis
- Units, rounding and acceptable formula tolerances
3. Define serving and piece load
- Serving size, gummies per serving and target gummy mass
- Total solids and room for the selected materials
- Consumer-use direction supplied for label review
4. Define the complete formula
- Pectin or gelatin direction and dietary-positioning request
- Sweeteners, acids, flavors, colors, coatings and co-ingredients
- Known incompatibilities, sensory limits and excluded inputs
5. Match method to question
- Component identity, purity or finished amount being decided
- Need to distinguish stereoisomers or carbohydrate interferents
- Sample preparation, matrix scope, units and decision rule
6. Define finished-product evidence
- Individual analyte amounts and any calculated ratio
- Uniformity or other batch-representation plan where applicable
- Microbiological, physical and other agreed quality attributes
7. Reconcile label and claims
- Supplement Facts basis, serving, units and ingredient naming
- Other ingredients, directions, warnings and target market
- Claim substantiation owner and final artwork approval
8. Connect package and commercial scope
- Bottle, closure, count, protection and distribution conditions
- Stability protocol and product-package time points
- Volume stage, destination, timing and required documents
One field should answer one decision
Use this as a discussion map, not as a pre-approved Sucotond specification.
| Field | Record before feasibility | Evidence or decision |
|---|---|---|
| Component identity | Exact isomer, supplier material, grade, lot and physical form | Supplier specification, identity/composition record and incoming decision |
| Individual amounts | Amount of every inositol component per serving and units | Formula, theoretical input, label basis and agreed verification |
| Requested ratio | Named numerator/denominator, calculation and tolerance | Derived only from controlled individual values; never replaces them |
| Serving/load | Piece count, gummy mass, total active solids and overage rationale if any | Bench feasibility, process review and approved formula |
| Gummy matrix | Base, water, acids, sweeteners, flavors, colors, coating and co-ingredients | Process, sensory, compatibility and sample approval |
| Analytical plan | Analyte, matrix, preparation, selectivity, units, time point and acceptance rule | Laboratory consultation and scientifically valid project method |
| Label/claims | Serving, ingredient names, amounts, directions, warnings, claims and market | Formula reconciliation, substantiation and responsible-party approval |
| Package/stability | Commercial pack, storage, distribution, protocol and relevant attributes | Product-package-time evidence and quality disposition |
Carry identity through the commercial batch
Supplier material
Name each isomer, supplier, grade, form, composition basis and lot documents.
Incoming decision
Set component specifications, identity approach, sampling and quality disposition.
Approved formula
Lock individual inputs, serving, piece load, matrix, label basis and tolerances.
Commercial process
Connect master record, batch record, in-process controls and representative sample.
Finished evidence
Use agreed analytes, matrix-appropriate methods, specifications and batch decision.
Label and time
Reconcile released artwork, package, stability time points and change control.
Public references help frame questions; they do not approve this project
Inositol includes multiple stereoisomers
The U.S. National Library of Medicine's PubChem record describes inositol as a group of nine stereoisomers and notes common use of the name for myo-inositol. That identity context is why a buyer should name each intended component. It is not a Sucotond material confirmation, formula, result or efficacy statement.
Read 21 CFR 184.1370 narrowly
The current regulation identifies inositol or myo-inositol and describes listed conditions for use as a direct human food ingredient. That text does not approve D-chiro-inositol, a dietary-supplement formula, a ratio, dose, claim or finished gummy. Regulatory status and intended use still require project-specific review.
A method name is not enough
Published research includes an HPLC-MS/MS method designed to distinguish myo-inositol from other stereoisomers and same-molecular-weight sugars in nutritional supplements, and HILIC research separating myo-inositol from allo- and D-chiro-inositol plus carbohydrate interferents. A newer GC-MS/MS paper concerns human serum. Together these are method-development context—not a Sucotond result. They show questions to ask about selectivity, sample preparation and matrix; they do not designate one universal gummy method or prove that a serum method fits a gummy.
- HPLC-MS/MS method for myo-inositol in nutritional supplements
- HILIC separation research for inositol isomers and carbohydrates
- GC-MS/MS research for myo- and D-chiro-inositol in serum
The approved formula must connect to controlled records
FDA's dietary-supplement CGMP guide discusses component identity and specifications, appropriate scientifically valid tests or examinations, finished-product specifications, master manufacturing and batch records, packaging and label controls, and quality-control review. FDA also explains that manufacturers and distributors are responsible for ensuring supplement claims are truthful, not misleading and adequately substantiated. These sources define responsibilities; they do not pre-approve an inositol gummy.
FDA dietary-supplement CGMP guide · FDA dietary-supplement Q&A · FDA claims-substantiation guidance
Brand / specification owner
Defines intended market, named ingredients, individual amounts, serving, claims, package, acceptance criteria and required disclosures; approves the commercial brief and artwork.
Sucotond USA
Coordinates non-confidential requirements, questions, document requests and commercial communication with the factory. The U.S. office does not replace legal, laboratory or quality approval.
Factory and quality unit
Reviews material and process feasibility, controls approved records, makes applicable quality decisions and confirms which documents or results exist for the actual project.
Qualified laboratory / advisor
Evaluates method and matrix suitability or regulatory/claim questions within the agreed scope. No laboratory, advisor, result or opinion is promised by this page.
Inositol gummy project questions
Are myo-inositol and D-chiro-inositol the same specification item?
No. They are different stereoisomers. Name each intended component, its supplier material, individual amount, serving basis and testing decision instead of using “inositol” as one interchangeable field.
Does the inositol food regulation approve D-chiro-inositol or a supplement ratio?
No. 21 CFR 184.1370 identifies inositol or myo-inositol and describes listed direct-food-use conditions. It does not approve D-chiro-inositol, a dietary-supplement formula, a ratio, dose, claim or finished gummy.
Is a requested myo- to D-chiro-inositol ratio a default manufacturing standard?
No. It is a buyer-supplied formula input that must be translated into individual component amounts, serving, tolerances, label wording and a feasible quality plan. It is not a default or FDA-required ratio.
Can a gummy carry any requested inositol serving amount?
That cannot be assumed from a web page. Selected materials, individual amounts, piece count, gummy mass, water and acid system, sensory targets, process behavior, uniformity, package and stability plan require project-specific feasibility review.
What evidence should an inositol gummy project define?
Define supplier identity and composition records, incoming specifications, approved formula and label basis, sample approval, master and batch records, applicable component and finished-product tests, method and matrix scope, package and stability evidence, quality disposition and document disclosure rights.
Request an inositol gummy feasibility map
Share intended isomer(s), individual amounts and any requested ratio, serving, gummy system, package, market, volume stage, evidence expectations and timing. The review identifies open questions; it is not a formula, quote, method, result or production commitment.
Sucotond USA
U.S. sales and project coordination
Brooklyn, NY 11214